Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06232642 · ClinicalTrials.gov registry record · NA
Effects of Lactoferrin-enriched Whey on Iron Status in Females
A NA study of Serum Ferritin, sponsored by Utah State University.
- Active
- Registry status
- NA
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT06232642: Active NA study of Serum Ferritin, sponsored by Utah State University.
NCT06232642 is a NA study of Serum Ferritin that is active but no longer recruiting, run by Utah State University. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06232642, a NA study of Serum Ferritin, is active but no longer recruiting, sponsored by Utah State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this work is to study the effects of twice daily ingestion of a whey protein, rice protein, or maltodextrin drink enriched with lactoferrin- (200 mg), iron (6 mg) and vitamin B12 (5.2 µg) for 16-weeks on iron metabolism and inflammatory markers in active young females. It is expected that the females consuming containing lactoferrin-, iron, and vitamin B12-enriched whey will 1) improve serum ferritin status; 2) reduce inflammation; 3) improve markers of iron metabolism, such as Hemoglobin (Hb), red blood cell count (RBC) and hematocrit (Hc) compared to women who consume the rice protein or maltodextrin control drink. Blood will be drawn before the beginning of the supplemental period (week 0) and end the end of the intervention phase (week 16).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Lactoferrin, iron and B12 in Whey Protein
- DIETARY_SUPPLEMENT Lactoferrin, Iron and B12 in Rice Protein
- DIETARY_SUPPLEMENT Lactoferrin, Iron and B12 in Maltrodextrin
Study Locations (1)
Utah
- Center for Human Nutrition Studies - Logan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
What the registry record for NCT06232642 still lists
NCT06232642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Serum Ferritin appearing as the primary indexed condition, and to 3 interventions - of which Lactoferrin, iron and B12 in Whey Protein is the first listed.
NCT06232642 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06232642 about?
NCT06232642 is a clinical study titled "Effects of Lactoferrin-enriched Whey on Iron Status in Females". The goal of this work is to study the effects of twice daily ingestion of a whey protein, rice protein, or maltodextrin drink enriched with lactoferrin- (200 mg), iron (6 mg) and vitamin B12 (5.2 µg) for 16-weeks on iron metabolism and inflammatory markers in active young females. It is expected tha...
What is the current status of trial NCT06232642?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 82 participants. The study started on 2024-03-01. Estimated completion is 2025-05-30.
What conditions does trial NCT06232642 study?
This clinical trial studies the following conditions: Serum Ferritin.
What interventions are being tested in trial NCT06232642?
The interventions under investigation include: Lactoferrin, iron and B12 in Whey Protein (DIETARY_SUPPLEMENT), Lactoferrin, Iron and B12 in Rice Protein (DIETARY_SUPPLEMENT), Lactoferrin, Iron and B12 in Maltrodextrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06232642?
This trial is sponsored by Utah State University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06232642 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06232642's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI